{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T16:42:47Z","timestamp":1786466567104,"version":"build-2736575974"},"reference-count":10,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jacc.2026.05.011","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T14:14:44Z","timestamp":1781705684000},"page":"667-669","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Interruption of Early Cardiovascular Risk Pathways With GLP-1-Based Therapy for Obesity"],"prefix":"10.1016","volume":"88","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6331-5224","authenticated-orcid":false,"given":"Brendan M.","family":"Everett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2866-9414","authenticated-orcid":false,"given":"John W.","family":"Ostrominski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2026.05.011_bib1","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.05.011_bib2","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.05.011_bib3","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.jacc.2025.04.059","article-title":"Impact of body mass index, central adiposity, and weight loss on the benefits of tirzepatide in HFpEF: The SUMMIT trial","volume":"86","author":"Borlaug","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.05.011_bib4","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1016\/S0140-6736(25)01375-3","article-title":"Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial","volume":"406","author":"Deanfield","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2026.05.011_bib5","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S2213-8587(24)00363-2","article-title":"Estimating direct tissue effects versus weight loss effects of incretin-based drugs for obesity on various chronic conditions","volume":"13","author":"Sattar","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"10.1016\/j.jacc.2026.05.011_bib6","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.jacc.2026.04.044","article-title":"Comprehensive long-term changes in cardiovascular risk biomarkers with tirzepatide: a SURMOUNT-1 post hoc analysis","volume":"88","author":"Sattar","year":"2026","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.05.011_bib7","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.7326\/ANNALS-24-02623","article-title":"Improvements in cardiometabolic risk factors by weight reduction: a post hoc analysis of adults with obesity randomly assigned to tirzepatide","volume":"178","author":"Linetzky","year":"2025","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2026.05.011_bib8","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.cmet.2018.07.003","article-title":"Remission of human type 2 diabetes requires decrease in liver and pancreas fat content but is dependent upon capacity for \u03b2 cell recovery","volume":"28","author":"Taylor","year":"2018","journal-title":"Cell Metab"},{"key":"10.1016\/j.jacc.2026.05.011_bib9","doi-asserted-by":"crossref","first-page":"7385","DOI":"10.1111\/dom.70143","article-title":"Tirzepatide and the 10-year predicted risk of cardiovascular disease and type 2 diabetes in adults with obesity and prediabetes: a post hoc analysis from the three-year SURMOUNT-1 trial","volume":"27","author":"Hankosky","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jacc.2026.05.011_bib10","doi-asserted-by":"crossref","first-page":"e89","DOI":"10.1161\/CIR.0000000000001258","article-title":"Forecasting the economic burden of cardiovascular disease and stroke in the United States through 2050: a presidential advisory from the American Heart Association","volume":"150","author":"Kazi","year":"2024","journal-title":"Circulation"}],"container-title":["JACC"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109726065666?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109726065666?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T15:48:32Z","timestamp":1786463312000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109726065666"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":10,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0735109726065666"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2026.05.011","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interruption of Early Cardiovascular Risk Pathways With GLP-1-Based Therapy for Obesity","name":"articletitle","label":"Article Title"},{"value":"JACC","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2026.05.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2026.04.044","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}